Shahram Sharif Presents Liva Healthcare at LSI USA '23

Transcription

Shahram Sharif  0:06  

Good morning everybody. My name is Shahram Sharif. I'm the Chief Executive of Liva Healthcare. Liva healthcare is a digital health company. Our mission is to reverse and prevent chronic diseases such as diabetes type two, and obesity. just at a glance. We have been around since 2015. We're currently a team of about 120 people across three countries Copenhagen, office London and Berlin, served customers across 12 countries. We have currently three treatments commercialized for diabetes, step two, pre diabetes and obesity. And we work with customers, both in in public health as well as life sciences and private insurance companies. To date, we have raised about 25 million. So, basically, we are a, we develop digital therapeutics, which are basically software's as medical medical device to treat, prevent or manage diseases, and we augment them with behaviors, things like science led health coaching. Unlike many digital health companies, we're strongly rooted in science and have a lot of clinical evidence for our treatments. And we are used to deliver outcomes as a service, we own the outcome of our treatments, and we're used to work within a value based healthcare model. Just quickly on burden of chronic disease, I'm sure many of you know it today, one out of three people worldwide are suffering from a chronic disease. So that's about 2.2 billion people and the next seven years, they're about half a billion more going to be added to it. And according to who this is consuming about 80% of all total healthcare spending. If you look at the five leading chronic diseases, this is costing about 2 trillion a year. Now what is really interesting is that 80% of all chronic diseases are driven by lifestyle factors, such as diet, and exercise, and other habits and behavior. And that is where we are focused on so our mission is to focus on lifestyle related chronic disease, and go for reversal, beyond just managing them. So simply put our solutions consists of just two components. One is a technology platform. And another one is actual human coaching. That is scalable using the technology platform, essentially three components, a patient facing app, which is used when patients are on boarded into our programs to collect their data and track the progress and allow them to interact with our clinicians and health coaches, health and clinician dashboard that basically tracks the progress and sees all the data from the funded patients and members, and the analytic elements and an engine which basically crunches all the data using machine learning artificial intelligence to further personalize and optimize the the treatments with patients. taking a deeper look, there's a lot more under the hood, I'll not go into all the details. But you know, we're really keen on using behavior science, certified coaches, and use the technology platform to make it scalable. We use AI and data analytics to continuously improve the outcomes and personalization and make coaches more efficient in what they do. When it comes to technology, we're not just deploying technology for the sake of technology. But our continuous efforts are around finding the sweet spots to get to the best possible outcomes at scale. There are many studies that shows that you know, if you apply more human elements coaching, because it's all about behavior and habit change, you will have better outcomes. However, that is not scalable. On the other side of the scale. If you use a lot of technology that's very scalable, but the outcomes are poor. So we are really in the sweet spot of the right mix between technology and human coaching. As mentioned earlier, we are driven by clinical evidence and our outcomes are very attractive. So we are showing engagement rates up to 80%. So patients stay on our program up to nine to 12 months, we have shown 80% Decrease in HVA1C for patients with diabetes and prediabetes 47% remission of prediabetes and up to 39% of patients with diabetes that type two, completely reversing their chronic conditions, off medication, all that those are significant results, both in our city studies and even better outcomes in our real world evidence. Currently we're covering about 40,000 lives. We have millions of minutes of video interaction with our patients with our coaches, which we use as I mentioned earlier, through machine learning to optimize the treatments, we have applied more than 400 times and treatments to, to our members to date and we are one of the top providers of NHS in the UK. In a value based contracting model, we are ready to scale our commercial achievements. Just as a example in the NHS, which is one of the toughest markets to get into. As some of you might know, we have shown over the last couple of years that we have been able to increase our market share by almost three times, we have increased the part of the members who choose for digital versus traditional face to face treatments by by a factor of three. And by applying more and more technology, we have made the whole unit economics significantly more efficient by a factor of two and a half and all of that has shown significant growth for us commercially. In terms of commercial growth and expansion. There are basically two elements there is the therapeutic areas that we cover that we are expanding. So we have currently in a portfolio beyond the three commercialized treatments for obesity, pre diabetes, and type two, we are currently working on additional treatments that will come out in the next two to three years with different partners which give us access to additional almost 300 billion in assets per market, and other expansion axis is to expand through different markets. To date, we have done pilots across 12 countries, which has given us a lot of information for different markets, currently serving reimburse markets and lifetime customers in Scandinavia, UK, Germany and Benelux. And we have plans to expand that to 10 additional markets across Europe, Middle East and Australia in the coming few years. We are currently raising 15 50 million round to help us accelerate our growth to go from 3 million annual recurring revenue, which we are at today. To break through to 50 million revenue in next four years, we will be profitable. Within the next two to three years. We have a very strong revenue diversification across three or four different customer segments, public payers, private insurance companies, lifesigns. Players and retail. As mentioned earlier, expanding to six therapeutic areas beyond the current three and covering lives from 40,000. Today to about six 600,000 In about four or five years. I'm here today representing our company which is active in Europe. Why I'm here because I believe there's a tremendous opportunity for US investors. Hopefully some of you are here in the room. Because we believe there's a massive unreal investment in digital health across Europe versus us when you look at the market potential. So the digital health market is larger in Europe compared to US is growing faster in Europe compared to us. Yet, if you look at the total investments done in 21, it's almost one on four. So we believe there's a significant opportunity for US investors to invest in European companies like like ours. quickly about the team. This is my third company in medtech and digital health space. I was actually here three years ago pitching for my previous company, which we sold last year in cardiology. Very excited to be here again. Exactly thing consists of our CEO and the CFO who are all serial entrepreneurs, having done scalings across different industries. We are backed by key investors in Europe, mostly one of them that might be known as Athos, which is a family office in Germany, who are the same investors beyond behind beyond tech. So they've done pretty well and they are backing us into our next next rounds. So thank you for attention. Feel free to reach out to me for any discussions or conversation we could have to find a potential fit. Thank you